ST. LOUIS, Dec. 2 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company today announced that that it has entered into an employment agreement with Interim President and Chief Executive Officer David A. Van Vliet with a term through December 31, 2011. Mr. Van Vliet has served as Interim President and Chief Executive Officer since December 2008.
“This agreement reflects the tremendous job David has done leading KV during a very challenging and critical period and ensures continuity of his effective stewardship as we execute against our consent decree and seek to return to market,” said Terry Hatfield, Chairman of KV Pharmaceutical.
About KV Pharmaceutical Company
KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a subsidiary that competes with branded products, and Ther-Rx Corporation, the company’s branded drug subsidiary.
CONTACT: Michael Anderson for KV Pharmaceutical Company, +1-314-645-6600
Web site: http://www.kvpharmaceutical.com/
